MOTS-c
A 16-amino-acid mitochondrial-derived peptide that activates AMPK to mimic the metabolic effects of exercise and improve insulin sensitivity.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the 12S ribosomal RNA gene of mitochondrial DNA, identified in 2015 as the first member of its class. It is secreted from mitochondria into circulation in response to metabolic stress and exercise, where it functions as a hormone-like signal that activates AMPK, increases glucose uptake, promotes fat oxidation, and improves insulin sensitivity. Endogenous levels rise transiently with exercise and decline with age, positioning MOTS-c as a researched exercise mimetic and longevity intervention. Evidence is strong and replicated in rodents but human efficacy remains unestablished, with the first parent-molecule human trial only registered in 2026.
Class
Mitochondrial-derived peptide (16-amino-acid)
Half-life
Rapidly cleared from plasma (reported minutes to ~4-6 hours across sources); downstream gene-expression effects persist for hours
Routes
Subcutaneous, Intramuscular, Intravenous (research)
Category
Immune & Mitochondrial
Researched benefits
What it's studied for
Improved insulin sensitivity
Preclinical rodent studies consistently show MOTS-c improves glucose tolerance and reverses diet-induced and age-related insulin resistance by increasing insulin-independent glucose uptake. This is one of the most replicated effects and the focus of the first human trial.
Exercise mimicry
By activating AMPK, MOTS-c reproduces many molecular adaptations of physical exercise — GLUT4 translocation, fatty acid oxidation, and mitochondrial biogenesis — generating interest for populations where exercise is difficult. Endogenous MOTS-c itself rises with exercise in both mice and humans.
Metabolic homeostasis and fat oxidation
AMPK activation phosphorylates acetyl-CoA carboxylase, releasing the brake on fatty acid entry into mitochondria and shifting metabolism toward oxidative fuel use. In obese mice this produced reduced visceral adiposity and body weight without reduced food intake.
Anti-aging / metabolic rejuvenation
Circulating MOTS-c declines with age; in aged mice (22-23 months), three weekly injections restored treadmill performance and metabolic flexibility, suggesting a replacement-therapy hypothesis. Human longevity translation is unestablished.
Mitochondrial biogenesis and quality control
MOTS-c activates the PGC-1α pathway driving new mitochondrial synthesis and, in newer preclinical work, enhances autophagy and protects mitochondrial function against oxidative and ischemic stress.
Anti-inflammatory signaling
Emerging 2026 preclinical studies report MOTS-c suppresses NLRP3 inflammasome activation and reduces fibrosis in diabetic and cardiac injury models, extending its metabolic role into inflammation control.
Mechanism
How it works
MOTS-c belongs to the mitochondrial-derived peptides (MDPs) — a class of small bioactive peptides encoded within mitochondrial DNA open reading frames that were historically thought to encode only ribosomal RNAs. Its discovery reframed mitochondria as endocrine organs that produce their own signaling molecules rather than merely receiving nuclear instructions. Under metabolic stress conditions such as fasting, caloric restriction, and exercise, mitochondria translate and release MOTS-c into circulation, where it acts on skeletal muscle, adipose tissue, and liver.
The core pharmacologic mechanism is agonism of AMP-activated protein kinase (AMPK), the cellular energy master-switch also targeted by metformin, exercise, and caloric restriction. AMPK activation increases GLUT4 translocation to the muscle membrane (raising glucose uptake independent of insulin), phosphorylates acetyl-CoA carboxylase to promote fatty acid oxidation, activates PGC-1α to drive mitochondrial biogenesis, and suppresses anabolic pathways including mTORC1, lipogenesis, and gluconeogenesis. The net effect is a metabolic shift toward oxidative capacity and glucose disposal — essentially the molecular signature of exercise.
The upstream trigger was clarified by later work identifying MOTS-c as a regulator of folate and one-carbon metabolism: MOTS-c inhibits the folate cycle and de novo purine biosynthesis, reducing methionine synthesis and elevating AMP, which activates AMPK via the AICAR pathway. This places MOTS-c at a specific methionine-cycle node upstream of AMPK, offering a mechanistic explanation for its tissue-selective effects.
MOTS-c also functions as a retrograde mitochondrial-to-nuclear signal, translocating to the nucleus under metabolic stress to modulate nuclear gene expression around metabolism and stress response. It acts both cell-autonomously (autocrine action on local AMPK and the folate cycle) and systemically as a circulating endocrine signal reaching distant tissues, a dual action unusual for a mitochondrial-derived molecule.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Ships as a white lyophilized powder in 5 mg or 10 mg vials. Reconstitute with bacteriostatic water: 10 mg + 2 mL BAC water = 5 mg/mL (a 5 mg dose = 1 mL = 100 units on a U-100 insulin syringe), or 10 mg + 1 mL = 10 mg/mL (a 5 mg dose = 0.5 mL = 50 units; a 10 mg dose = 1 mL = 100 units). The higher 10 mg/mL concentration is generally preferred to keep single injections under 1 mL. Add water down the vial wall, do not shake — swirl gently until a clear colorless solution forms.
Beginner
- Dose
- 5 mg (5,000 mcg)
- Frequency
- 2x weekly (e.g. Mon/Thu)
- Timing
- Morning, fasted if possible to align with natural AMPK circadian activation
- Duration
- 8-12 weeks to assess response
- Route
- Subcutaneous
Monitor for hypoglycemic symptoms during first 2-3 doses; expect possible mild transient fatigue in the first week as metabolic adaptation occurs. Run baseline fasting insulin, glucose, and HbA1c.
Intermediate
- Dose
- 10 mg (10,000 mcg)
- Frequency
- 2-3x weekly
- Timing
- Morning, fasted, ideally on training days
- Duration
- Ongoing with periodic assessment
- Route
- Subcutaneous
Escalate to this tier after 8-12 weeks of positive response at the beginner dose. Athletic users often align the three weekly doses with their hardest training days for synergistic AMPK effect. Monitor fasting insulin, glucose, and HbA1c quarterly.
Advanced
- Dose
- 10 mg (dose ceiling ~10 mg per injection)
- Frequency
- 2-3x weekly
- Timing
- Morning, fasted, cycled long-term
- Duration
- Long-term cycling with quarterly labs
- Route
- Subcutaneous
Advanced use emphasizes integration into a broader longevity stack rather than dose escalation — the signaling system appears to saturate above ~10 mg per injection, beyond which no additional benefit is documented.
- Typical range across sources: 5-10 mg (5,000-10,000 mcg) per injection, 2-3 times weekly (some protocols up to 3-5x weekly), in 4-12 week cycles.
- Intermittent dosing (2-3x weekly) is preferred over daily because it mimics the pulsatile release of endogenous MOTS-c during metabolic stress and limits sustained AMPK/mTOR-suppression concerns.
- Morning, fasted timing aligns with natural AMPK circadian activation; pairing with the hardest training days is an optional synergy strategy.
- No human clinical trial has established a reference dose; all protocols above are community/practitioner conventions, not clinically validated regimens.
- Weight-based dosing is not established — standard flat dosing is used. Keep single injection volumes under 1 mL to reduce discomfort and lipoatrophy risk; split larger volumes across two sites.
- Reconstituted solution: refrigerate at 2-8°C and use within 30 days; store lyophilized powder refrigerated and protected from light; never freeze.
- Expected timeline: mild fatigue weeks 1-2, energy/exercise changes weeks 3-4, measurable fasting insulin/glucose shifts weeks 6-8, body-composition changes weeks 10-12.
Evidence
Research & clinical studies (10)
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
The original discovery paper showed MOTS-c inhibits the folate cycle and de novo purine biosynthesis to activate AMPK, and that systemic administration prevented age-related and diet-induced insulin resistance and obesity in mice, establishing it as a mitochondrial hormone.
PMID 25738459MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation
Summarizes evidence for MOTS-c as a circulating insulin-sensitizing and exercise-mimetic peptide acting on lipid oxidation, glucose homeostasis, and mitochondrial quality control, and its potential as a target for metabolic and age-related conditions.
PMID 30788534MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation
MOTS-c improved survival of transplanted soft tissue by reducing lysosomal membrane damage and suppressing pyroptosis via inhibition of PLA2G4A signaling, restoring cellular homeostasis in ischemic tissue.
PMID 42153537LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation and mitochondrial protection
An engineered R13A-MOTS-c variant with enhanced LAT1-mediated cellular uptake activated Nrf2 antioxidant signaling and protected mitochondrial function in lung cells exposed to radiation injury.
PMID 42142418Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction
The mitochondrial-derived peptides humanin and MOTS-c were reduced in atrial fibrillation patients and inversely correlated with severity; administration in mice reduced AF inducibility and attenuated fibrosis and mitochondrial dysfunction.
PMID 42193373MOTS-c attenuates hyperoxia-induced neonatal cardiac injury by inhibiting oxeiptosis via maintaining the KEAP1-PGAM5 interaction
MOTS-c protected neonatal hearts from hyperoxia-induced damage by inhibiting oxeiptosis through interaction with KEAP1, reversing cardiac dysfunction, fibrosis, and hypertrophy in hyperoxia-exposed neonatal mice.
PMID 42128272Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model
MOTS-c suppressed NLRP3 inflammasome activation in circulation and cardiac tissue of diabetic rats while lowering blood glucose and inflammatory markers, suggesting a route to reduce inflammation-related cardiovascular complications in type 2 diabetes.
PMID 42321010Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells
In human mesenchymal stromal cells MOTS-c activated metabolic signaling but blunted reparative function, highlighting context-dependent effects of the peptide on cell repair.
PMID 42324588Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study
Circulating MOTS-c was reduced in Hashimoto's thyroiditis patients, reflecting integrated autoimmune and metabolic dysregulation and supporting MOTS-c as a candidate metabolic-inflammatory biomarker.
PMID 42278864MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia
MOTS-c partially protected against skeletal muscle deterioration in the C26 cancer-cachexia model, extending its muscle-metabolic role into wasting conditions.
PMID 42266945Combinations
Stacking & blends
MOTS-c + SS-31 (Mitochondrial Optimization)
Anti-aging, fat loss, and mitochondrial protection
Pairs two mitochondrial peptides with complementary mechanisms — MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in aging, metabolic dysfunction, and exercise-performance contexts.
MOTS-c + NAD+ / NMN longevity stack
Mitochondrial function and metabolic flexibility for longevity
MOTS-c activates AMPK and drives mitochondrial biogenesis while NAD+ precursors fuel sirtuins and mitochondrial respiration — different mechanisms converging on the same target. A common triple adds Urolithin A (500-1000 mg daily) for mitophagy/quality control.
Advanced metabolic-longevity protocol
Multi-pathway longevity intervention
Targets AMPK (MOTS-c), SIRT1 (resveratrol/pterostilbene), mitophagy (Urolithin A), and mTOR regulation (optional rapamycin) simultaneously, built around exercise as the cornerstone rather than a replacement for it.
MOTS-c + GH-axis support (non-interfering)
Metabolic optimization alongside GH-axis support
MOTS-c is considered non-interfering with GH secretagogues that work through a different pathway; BPC-157 is similarly compatible. Note that AMPK activation opposes mTOR, so combining with aggressive anabolic agents may blunt hypertrophy signaling.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy and lactation (no safety data)
- Pediatric and adolescent use (developmental effects unknown)
- Active malignancy (AMPK activation can be anti- or pro-cancer depending on context)
- Known hypersensitivity to MOTS-c or excipients
- Brittle diabetes or severe hypoglycemia history (monitor closely)
- Concurrent maximal-dose metformin or other AMPK activators (redundant activation)
- Concurrent insulin, sulfonylureas, or meglitinides (additive hypoglycemia risk)
- Aggressive muscle-building phases (AMPK opposes mTOR and may blunt hypertrophy)
Human safety data is limited to small Phase 1 pharmacokinetic studies and community-reported use; preclinical rodent studies have not surfaced significant toxicity at researched doses. Community reports note histamine-type injection reactions can be severe enough to force discontinuation, and blood sugar can drop meaningfully when combined with other glucose-lowering agents. Given the sparse long-term human database, a low threshold for discontinuation is appropriate — stop for pregnancy, new malignancy diagnosis, persistent severe fatigue beyond the adaptation period, recurrent hypoglycemia, or any severe hypersensitivity reaction.
FAQ
MOTS-c — common questions
What is MOTS-c?
MOTS-c (mitochondrial ORF of the 12S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene of mitochondrial DNA. Identified in 2015 at USC by Pinchas Cohen and Changhan Lee, it was the first member of the mitochondrial-derived peptide (MDP) family and acts as a hormone-like signal that activates AMPK to regulate metabolism, glucose uptake, and insulin sensitivity.
Does MOTS-c work for weight loss?
Preclinical animal data shows MOTS-c reduced visceral adiposity and body weight in obese mice without reducing food intake, and its AMPK-driven fat oxidation supports metabolic improvements that favor fat loss. However, it is not a primary weight-loss tool like GLP-1 agonists (semaglutide, tirzepatide) — it works slowly and subtly on metabolic flexibility rather than appetite, and is best positioned as an adjunct to diet and exercise. Human efficacy data is very limited.
Can MOTS-c reverse aging?
In aged mice, MOTS-c restored exercise capacity, improved mitochondrial function, and reversed age-related metabolic dysfunction — a genuinely striking preclinical signal. Endogenous MOTS-c also declines with age in humans, and the decline correlates with metabolic deterioration. Whether exogenous replacement reproduces these effects in humans is not established; no large human longevity trials have been completed, so longevity claims should be treated as mechanistically plausible but preclinical.
What is a typical MOTS-c dosing protocol?
Community protocols use 5-10 mg subcutaneous 2-3 times weekly, dosed in the morning and fasted if possible to align with AMPK circadian activation. Beginners often start at 5 mg twice weekly for 8-12 weeks; intermediate users run 10 mg 2-3x weekly. Intermittent dosing is preferred over daily to mimic the natural pulsatile release, and the effective ceiling is about 10 mg per injection. No human clinical trial has validated any of these regimens.
Is MOTS-c FDA approved?
No. MOTS-c has no FDA or other regulatory approval for any indication and is sold strictly as a research-use-only compound. It is in early clinical investigation — the first parent-molecule human trial (insulin sensitivity) was registered in April 2026 — but has not reached registrational trials. For sport, WADA lists it as a prohibited metabolic modulator.
Should I take MOTS-c if I already take metformin?
Both activate AMPK, though through different upstream routes (MOTS-c via the folate cycle, metformin via complex I inhibition), so combining them is somewhat redundant. It is not strictly contraindicated, but most practitioners use one primary AMPK activator at a time or reduce metformin dose if combining, with careful glucose monitoring since the combined effect could lower glucose more than either alone.
Can MOTS-c be stacked with NAD+?
Yes — MOTS-c and NAD+ (or precursors NMN/NR) are a common longevity stack. MOTS-c activates AMPK and drives mitochondrial biogenesis while NAD+ fuels sirtuins and respiration, converging on mitochondrial function through different mechanisms. A frequent combination adds Urolithin A for mitophagy, targeting biogenesis, sirtuin activation, and mitochondrial quality control together.
Can I use MOTS-c while building muscle?
MOTS-c's AMPK activation opposes mTOR, the main anabolic signal for muscle protein synthesis, creating theoretical concern during aggressive hypertrophy phases. In practice the effect appears modest and many users train on MOTS-c without notable muscle loss, but many experienced practitioners pause it during dedicated bulking and resume during cutting or maintenance where the metabolic benefits are more valuable.
